Abstract
ObjectiveTo aid in the selection of the most suitable therapeutic option in patients with diagnosis of rheumatoid arthritis according to the phase of disease, through the review of articles that identify omics biological markers.MethodsA systematic review in PubMed/Medline databases was performed. We searched articles from August 2014 to September 2019, in English and Spanish, filtered by title and full text; and using the terms "Biomarkers" AND “Rheumatoid arthritis".ResultsThis article supplies an exhaustive review from research of objective measurement, omics biomarkers and how disease activity appraise decrease unpredictability in treatment determinations, and finally, economic, and clinical outcomes of treatment options by biomarkers’ potential influence. A total of 122 articles were included. Only 92 met the established criteria for review purposes and 17 relevant references about the topic were included as well. Therefore, it was possible to identify 196 potential clinical biomarkers: 22 non-omics, 20 epigenomics, 33 genomics, 21 transcriptomics, 78 proteomics, 4 glycomics, 1 lipidomics and 17 metabolomics.ConclusionA biomarker is a measurable indicator of some, biochemical, physiological, or morphological condition; evaluable at a molecular, biochemical, or cellular level. Biomarkers work as indicators of physiological or pathological processes, or as a result of a therapeutic management. In the last five years, new biomarkers have been identified, especially the omics, which are those that proceed from the investigation of genes (genomics), metabolites (metabolomics), and proteins (proteomics). These biomarkers contribute to the physician choosing the best therapeutic option in patients with rheumatoid arthritis.
Highlights
Rheumatoid arthritis (RA) is a chronic autoimmune disease which is progressive and often disabling characterized by joint inflammation and pain; it requires monitoring of disease activity to decide the optimal treatment
Biomarkers have the capacity to enhance payment for medical and pharmacy policies related with the therapeutic management in immune system disorders and inflammatory diseases; they has a potential impact on economic and clinical outcomes of treatment choices [2]
Current overview of omics‐based biomarkers of rheumatoid arthritis in clinical practice In 2010, new criteria for early classification of RA were published as a joint effort of the European League against Rheumatism/American College of Rheumatology (EULAR) and the American College of Rheumatology
Summary
Rheumatoid arthritis (RA) is a chronic autoimmune disease which is progressive and often disabling characterized by joint inflammation and pain; it requires monitoring of disease activity to decide the optimal treatment. Puentes‐Osorio et al Autoimmun Highlights (2021) 12:9 participation are associated with mental and physical health of the patients. The use of biomarkers as monitors of disease development may aid providers improve non-biologic and biologic drugs [1]. The aim of RA therapy is to keep and increase a prolonged state of health associated with quality of life by controlling symptoms, preventing structural joint damage, normalizing physical function, and getting better function in their activities. In patients with RA, treated either with methotrexate or biologic disease-modifying anti-rheumatic drugs (DMARDs), only 40–60% of them respond effectively as measured by at least 50% of improvement of signs and symptoms of the disease (by ACR criteria), whereas 15–30% develop adverse drug events [3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
